Enmetazobactam

Enmetazobactam

Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
CAS Number	1001404-83-6
PubChem CID	23653540
DrugBank	DB18716
ChemSpider	68025157
UNII	80VUN7L00C
KEGG	D12817
ChEMBL	ChEMBL4458276
Chemical and physical data
Formula	C11H14F2N4O5S
Molar mass	352.31 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C
InChI InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1 Key:HFZITXBUTWITPT-YWVKMMECSA-N

Enmetazobactam (AAI-101) is an antibiotic adjuvant drug which acts as a beta-lactamase inhibitor, preventing the breakdown of other antibiotic drugs. ^[1] Enmetazobactam was invented by a team of scientists at Orchid Pharma in India and then out-licensed to Allecra Therapeutics for further development. ^[2] In the United States and European Union, enmetazobactam is approved for use in the combination cefepime/enmetazobactam (Exblifep). ^{[3] [4]}

References

1. Lanier C, Melton T, Covert K (September 2024). "Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor". The Annals of Pharmacotherapy. 59 (6): 570–576. doi:10.1177/10600280241279904. PMID   39329253.
2. US patent No.7687488B2 Novel 2-substituted methyl penam derivatives, https://worldwide.espacenet.com/patent/search/family/038949982/publication/US7687488B2?q=pn%3DUS7687488 Archived 5 April 2024 at the Wayback Machine
3. New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
4. "Exblifep EPAR". European Medicines Agency (EMA). 25 January 2024. Archived from the original on 4 February 2024. Retrieved 3 February 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.